6600 — SciClone Pharmaceuticals (Holdings) Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- HK$11.81bn
- HK$9.70bn
- CNY3.16bn
Brief: Onerobotics (Shenzhen) To Procure Affiliate Of Co To Acquire 59.9% Stake Of Nanoleaf Limited, Others
Brief: OneRobotics (Shenzhen) Says Final Offer Price Under Global Offering Is HK$73.80 Per H Share
Brief: Sciclone Pharmaceuticals (Holdings) Announces Proposal For Privatisation Of Co By Silver Pegasus Investment
Brief: SciClone Pharmaceuticals Says Trading In Shares Halted
Brief: Sciclone Pharmaceuticals Says Sciclone And Menarini Establish License And Collaboration Deal
Brief: Sciclone Pharmaceuticals (Holdings) Posts HY Net Profit RMB630.2 Mln
Brief: Sciclone Pharmaceuticals (Holdings) Recommends Final Dividend Of HK$0.39 Per Share
Brief: Sciclone Pharmaceuticals Says China's Nmpa Approved Co's Investigational New Drug Application
Brief: SciClone Pharmaceuticals's Shareholder Reduces Stake In The Company For HK$418.9 Mln- HKEX Filing
Brief: Central Huijin's Long Position In Sciclone Pharmaceuticals Falls To 7.69% - HKEX Filing
Brief: Sciclone Pharmaceuticals Says Approval On Biologics License Application Of Danyelza
Brief: Central Huijin's Long Position In H-Shares Of SciClone Pharmaceuticals Falls To 11.92% - Filing
Brief: Menarini And Sciclone Sign Licensing Agreement To Develop Vaborem In China
Brief: Sciclone Pharmaceuticals Posts HY Net Profit RMB532.2 Mln
Brief: SciClone Pharmaceuticals Announces License And Collaboration Deal For Vaborem In China
Brief: Sciclone Pharmaceuticals Gets NMPA Approval Of IND Of Danyelza® (Naxitamab) And GM-Csf
Brief: Sciclone Pharmaceuticals Says Nmpa Accepted Investigational New Drug Application Of Danyelza & Granulocyte- Macrophage Colony Stimulating Factor
China's SciClone Pharma jumps most on record on upbeat results, buyback plan
Brief: Sciclone Pharmaceuticals Says For Year Net Profit Was RMB923.4 Million , Increase Of 22.5%